Titan Medical (NASDAQ:TMDIF – Get Free Report) and Perspective Therapeutics (NYSE:CATX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.
Profitability
This table compares Titan Medical and Perspective Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Titan Medical | N/A | -82.31% | -51.47% |
| Perspective Therapeutics | -4,096.66% | -27.40% | -23.16% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Titan Medical and Perspective Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Titan Medical | 0 | 0 | 0 | 0 | 0.00 |
| Perspective Therapeutics | 0 | 1 | 7 | 1 | 3.00 |
Institutional and Insider Ownership
0.0% of Titan Medical shares are held by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are held by institutional investors. 0.0% of Titan Medical shares are held by company insiders. Comparatively, 3.5% of Perspective Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Titan Medical and Perspective Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Titan Medical | $17.63 million | 3.23 | $6.95 million | $0.05 | 10.00 |
| Perspective Therapeutics | $1.43 million | 148.41 | -$46.51 million | N/A | N/A |
Titan Medical has higher revenue and earnings than Perspective Therapeutics.
Risk & Volatility
Titan Medical has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.
Summary
Perspective Therapeutics beats Titan Medical on 9 of the 13 factors compared between the two stocks.
About Titan Medical
Titan Medical Inc. operates as a medical technology company. It focuses on the development and licensing of robotic assisted surgical technologies. The company is headquartered in Toronto, Canada.
About Perspective Therapeutics
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.
Receive News & Ratings for Titan Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Medical and related companies with MarketBeat.com's FREE daily email newsletter.
